Myriad Genetics reports Q3 2026 results and raises revenue guidance

ITEM 2.02 Results of Operations and Financial Condition.

On November 4, 2026, Myriad Genetics, Inc. announced its financial results for the three months ended September 30, 2026.¹ The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K² and incorporated herein by reference.

Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhibit 99.1, contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in Exhibit 99.1 to this Current Report on Form 8-K regarding these forward-looking statements.

ITEM 9.01 Financial Statements and Exhibits.

Exhibit

Number Description

99.1 Earnings release dated November 4 , 2026 for the three months ended September 30, 2026.²

104 Cover Page Interactive Data File² (embedded within the Inline XBRL document).

The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Current Report on Form 8-K.

Limitation on Incorporation by Reference . In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and in Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYRIAD GENETICS, INC.

Date: November 4, 2026 /s/ Benjamin R. Wheeler

Benjamin R. Wheeler

Chief Financial Officer

Myriad Genetics Reports Third Quarter 2026 Financial Results;

Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution

Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives

Highl ights

• Third quarter 2026 revenue was $202.7 million, representing a 6% sequential increase and a 1% decrease year-over-year.³ Higher Cancer Care Continuum (CCC) product mix and continued progress on payer engagement and revenue cycle management initiatives drove total average revenue per test increases of 7% sequentially and 1% year-over-year, partially offset by total test volume declines of 1% and 2%, respectively.⁴

• On October 19, 2026, entered into a definitive agreement to sell the Prenatal Health business to Labcorp for $210 million in cash, plus the value of related inventory at closing.⁵ Upon close, the sale is expected to be accretive to revenue growth and profitability, while strengthening the balance sheet.

• Raises mid-point of full-year 2026 revenue guidance to reflect third quarter 2026 results and current business trends for the remainder of 2026.⁹

SALT LAKE CITY, November 4, 2026 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its third quarter ended September 30, 2026, and raised the mid-point of revenue guidance for the full-year 2026.

1

"We have made meaningful progress on our path to accelerate profitable growth and strengthen the company's financial profile. Our third quarter 2026 financial results exceeded our expectations, led by our on-going focus on the Cancer Care Continuum (CCC). Average revenue per CCC test in the third quarter 2026 was higher than in the second quarter 2026 and reflects our team's ongoing work and early progress with payer engagement and revenue cycle management initiatives," said Sam Raha, President and CEO, Myriad Genetics. "The sale of our Prenatal Health business is a decisive step to support our strategic intent to increase profitable growth by focusing on the Cancer Care Continuum including screening, treatment selection and monitoring along with remission surveillance. We expect this action to benefit healthcare providers and patients we serve, as well as our employees and shareholders, and improve Myriad's revenue growth rate, profitability, and liquidity going forward. Lastly, we are increasing the mid-point of our full-year 2026 revenue guidance modestly, as we balance the positive third quarter 2026 performance with the timing of the sale of the Prenatal Health business, which is expected to close by early 2027.⁶"

Financial and Operational Highlights

• Third quarter 2026 test volume for Cancer Care Continuum and Mental Health increased 3% year-over-year to 239,000 tests, while Prenatal Health test volume decreased 11% to 138,000 tests, reflecting ongoing trends in the business, which the Company recently announced it plans to divest.

• Third quarter of 2026 average revenue per test increased 1% year-over-year reflecting product mix and incremental progress with payer engagement and revenue cycle management initiatives.

2

• The following table summarizes year-over-year testing volume changes in the company's core product categories:

Three months ended September 30, Nine months ended September 30,

Cancer Care Continuum and Mental Health Volume*

• The following table summarizes year-over-year revenue changes in the company's core product categories:

Three months ended September 30, Nine months ended September 30, (in millions)

Cancer Care Continuum and Mental Health Revenue*

*

On October 19, 2026, the Company entered into a definitive agreement to sell certain assets and liabilities of its Prenatal Health business. A Cancer Care Continuum and Mental Health volume and revenue subtotal is presented to provide additional information regarding the revenue of the businesses expected to remain